Insight Molecular Diagnostics Inc. Cash Flow Statement
IMDX|6 years of annual SEC 10-K data (FY2020-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 6 fiscal years. All figures from audited SEC 10-K filings.
Insight Molecular Diagnostics Inc. used $21M in operating cash flow and negative free cash flow of $21M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -7.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Net Income | -$60.7M | -$27.8M | -$72.9M | -$64.1M | -$29.9M | -$22.4M |
| Depreciation & Amortization | $1.6M | $1.7M | $1.5M | $800.0K | $313.0K | $344.0K |
| Operating Cash Flow | -$20.7M | -$23.3M | -$45.6M | -$35.9M | -$26.0M | -$19.7M |
| Capital Expenditures | $516.0K | $281.0K | $4.3M | $2.2M | $1.2M | $918.0K |
| Free Cash Flow | -$21.2M | -$23.6M | -$49.9M | -$38.2M | -$27.2M | -$20.6M |
| FCF Margin | -1127.3% | -1570.6% | -5209.6% | -1737.4% | -2237.4% | -1696.8% |